DNA methylation signatures separate HCC from nearby liver
Promoter methylation arrays in 30 HCC tumours vs surrounding tissue produced a validated signature that distinguished HCC from adjacent liver (independent of major risk factors), with other methylation panels tracking risk factors, progression, and survival after therapy.
Source
Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors
Study at a glance
- Design
- Other — Promoter methylation bead-array discovery in paired tumour/surrounding tissue with independent validation series
- N
- N=30 · Discovery: 30 HCC tumours with matched surrounding tissue (38 patients selected; 30 with paired samples)
- Population
- Surgical HCC patients at Edouard Herriot Hospital (Lyon) with cryopreserved tumour tissue
- Outcome
- Methylation signatures distinguishing HCC and correlating with risk factors/survival
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
At Edouard Herriot Hospital (Lyon), authors profiled promoter methylation with Illumina bead arrays covering 1505 CpG sites in 807 cancer-related genes across 30 HCC tumours and matched surrounding tissue, selected classifying CpG sites, and validated signatures in an independent HCC series.
What they found
They developed and validated a methylation signature that distinguished HCC from surrounding tissue and from other tumour types, independent of major risk factors. Distinct methylation panels associated with risk factors and progression; an independent promoter panel strongly correlated with survival after cancer therapy. A 20-CpG predictor heat map was shown on an independent series.
The limits
What it doesn't show
A methylation signature that classifies tissue is not by itself a population screening blood test. Survival correlations need careful external validation before treatment decisions. Array coverage is a cancer-gene panel, not the entire methylome.
Key terms
- Promoter methylation
- Epigenetic DNA methylation at gene promoters measured across hundreds of cancer-related loci.
- Surrounding tissue
- Matched non-tumour liver adjacent to HCC used as the within-patient comparator.
- Methylation signature
- Selected CpG set that classified HCC vs surrounding liver and validated independently.
- Illumina bead array
- Platform used to assay 1505 CpG sites in 807 cancer-related gene promoters.
- Risk-factor–linked methylation
- Separate panels associated with HBV/HCV/alcohol and progression, distinct from the core HCC-vs-liver signature.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
Core validated signature mainly separates?
Common questions
What samples built the discovery signature?
30 HCC tumours and their matched surrounding liver tissue.
What platform measured methylation?
Illumina bead arrays covering 1505 CpG sites in cancer-related gene promoters.
What did the validated signature do?
Distinguished HCC from surrounding tissue (and from other tumour types), independent of major risk factors.
Did any methylation panel track survival?
Yes — a distinct promoter panel strongly correlated with survival after cancer therapy.
Is this a finished blood screening test?
No — it is tissue methylation classification with clinical correlates, not a validated population blood assay.
More on Oncology outcomes